Krzysztof Wilk

No ORCID on file · 7 papers in corpus · active 2020-2025

Study types

  • article 5
  • other 1
  • rct 1

Condition tags

  • mesh:D017699 6
  • endometriosis 6
  • mesh:D004715 5
  • mesh:D004412 4
  • dysmenorrhea 4
  • dyspareunia 3
  • adenomyosis 1
  • mesh:D004414 1
other 2025
Prevalence of adenomyosis in adolescents: diagnostic process and symptoms. Systematic review
Ginekologia polska ·doi:10.5603/gpl.103105

BACKGROUND: Adenomyosis is a uterine disorder commonly associated with painful menstrual cycles, abnormal uterine bleeding, and dyspareunia, which can significantly impact fertility, pregnancy outcomes and overall quality of life. Recent li…

rct 2024
Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain
Fertility and sterility ·doi:10.1016/j.fertnstert.2024.06.009

OBJECTIVE: To evaluate the effect of relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate) for up to 2 years in the SPIRIT long-term extension study on functioning and health-relate…

article 2024
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study
Human Reproduction ·doi:10.1093/humrep/dead263

STUDY QUESTION: What is the efficacy and safety of long-term treatment (up to 2 years) with relugolix combination therapy (CT) in women with moderate to severe endometriosis-associated pain? SUMMARY ANSWER: For up to 2 years, treatment with…

article 2023
A Plain Language Summary to Learn About Relugolix Combination Therapy for the Treatment of Pain Associated with Endometriosis
Pain management ·doi:10.2217/pmt-2023-0052

WHAT IS THIS SUMMARY ABOUT?: This is a summary of research studies (known as clinical trials) called SPIRIT 1 and SPIRIT 2. The SPIRIT 1 and SPIRIT 2 studies compared how well a medicine called relugolix combination therapy worked in reliev…

article 2022
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)
Lancet (London, England) ·doi:10.1016/s0140-6736(22)00622-5

BACKGROUND: Endometriosis is a common cause of pelvic pain in women, for which current treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was eva…

article 2020
EFFICACY AND SAFETY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (SPIRIT 2)
·doi:10.1016/j.fertnstert.2020.08.238
article 2020
Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial
Fertility and sterility ·doi:10.1016/j.fertnstert.2020.02.114